Epigral Limited has informed the Exchange regarding a press release dated August 02, 2025, titled "Epigral Limited s Q1FY26 Revenue stood at ₹ 615 Crore".
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Epigral Limited reported Q1FY26 revenue of ₹615 crore, down 6% from ₹654 crore in Q1FY25, due to lower volumes and realizations. EBITDA fell 7% to ₹163 crore, but the EBITDA margin held steady at 27% on better efficiency and product mix. Reported PAT jumped to ₹160 crore, but this included a one-time ₹81 crore benefit from a drop in deferred tax liability; the underlying PAT was ₹79 crore versus ₹86 crore a year ago. The Derivatives & Specialty business contributed 50% of revenue. Balance sheet improved, with ROCE rising to 24% (from 21%) and Net Debt/EBITDA falling to 0.6x (from 1.6x). Plant utilization stood at 73%. Management said H2FY26 should be stronger than H1FY26, with ongoing capex to expand CPVC, Epichlorohydrin, and Wind-Solar Hybrid power capacity on track for timely commissioning, plus a new capex announcement planned for the remaining land parcel.
Mixed quarter for shareholders: headline profit looks strong but is inflated by a tax adjustment, while real earnings dipped slightly. However, stable margins, stronger returns, lower debt, and visible capacity expansion provide a constructive growth outlook, likely supporting a stable-to-positive stock reaction.